# First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors

> **NCT07265622** · PHASE1,PHASE2 · RECRUITING · sponsor: **Mabwell (Shanghai) Bioscience Co., Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** 7MW4911

## Key facts

- **NCT ID:** NCT07265622
- **Lead sponsor:** Mabwell (Shanghai) Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-12
- **Primary completion:** 2027-07
- **Final completion:** 2028-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07265622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07265622, "First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07265622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*